RTP Mobile Logo
Cancer Conference Update, Issue 1, 2017
Released June 2017

Featuring interviews with Drs Joseph Mikhael, Christopher Flowers and David P Steensma. (Audio Content)

CE Disclosures and Faculty Information

    Hematologic oncology and related blood disorders are some of the most rapidly evolving fields in all of medicine. Results presented at major conferences from a plethora of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing hematologist-oncologist must be well informed of these advances. To bridge the gap between research and patient care, this issue of Cancer Conference Update uses one-on-one discussions with hematologic oncology clinical investigators to provide perspectives on the integration of key data sets presented at the 2016 American Society of Hematology Annual Meeting into the practical management of various hematologic cancers and related blood disorders.


    • Recall new data with investigational agents demonstrating promising activity in hematologic cancers.
    • Appraise recent data on therapeutic advances and changing practice standards in multiple myeloma (MM), and integrate this information, as appropriate, into current clinical care.
    • Evaluate new approaches to the treatment of AL amyloidosis, and consider promising investigational agents that may be available and appropriate for patients in ongoing clinical trials.
    • Develop an understanding of the biologic rationale for and early efficacy and toxicity data with the use of immunotherapeutic approaches for patients with various lymphoma subtypes and MM.
    • Translate an understanding of the emerging efficacy and side-effect data with novel agents and combination regimens into treatment planning for patients with indolent and aggressive B-cell non-Hodgkin lymphomas.
    • Formulate an approach incorporating brentuximab vedotin and anti-PD-1/anti-PD-L1 antibodies alone or in combination regimens for the treatment of Hodgkin lymphoma.
    • Assess emerging high-level evidence supporting the use of maintenance lenalidomide in the treatment of chronic lymphocytic leukemia.
    • Recognize the potential role of novel agents and regimens in the management of newly diagnosed and relapsed/refractory acute and chronic leukemias and myelodysplastic syndromes.
    • Examine therapeutic strategies under investigation for the treatment of myelofibrosis to inform patients about protocol and clinical options.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity contains an audio component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-theart education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr MikhaelContracted Research: AbbVie Inc, Celgene Corporation, Sanofi Genzyme. Dr FlowersConsulting Agreements: Celgene Corporation, OptumRx Inc; Contracted Research: Acerta Pharma, Celgene Corporation, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc; Unpaid Consulting Agreements: Genentech BioOncology, Takeda Oncology. Dr SteensmaConsulting Agreements: Akebia Therapeutics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Foundation Medicine, Gilead Sciences Inc, Incyte Corporation, Novartis, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: June 2017 Expiration date: June 2018

Acknowledge and close

Listen to audio:
Cancer Conference Update, Issue 1, 2017
Released June 2017

Featuring interviews with Drs Joseph Mikhael, Christopher Flowers and David P Steensma. (Audio Content)

Read print: